Navigation Links
The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer

LAUSANNE, Switzerland, October 5, 2011 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today presented the 'JCA-Mauvernay Award' to Doctor Hirofumi Arakawa from the National Cancer Center Research Institute in Tokyo, for his basic research on the 'identification and characterization of p53 target genes' and to Doctor Mineo Kurokawa from the University of Tokyo, for his applied research on 'the molecular pathogenesis and therapeutic targets of hematological malignancies'. The ceremony was held during the 70th Annual Meeting of the Japanese Cancer Association (JCA) in Nagoya, Japan. This year the theme was 'Forward Strides for Cancer Research - Grounds for a Confident Future'. Professor Tetsuo Noda, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group™ presented both scientists with the 2011 Award for their outstanding and innovative research.

Dr Hirofumi Arakawa works in the division of Cancer Biology at the National Cancer Center Research Institute. Since 1999, he has focused on the p53 (protein 53) tumour suppressor, which functions mainly by controlling the expression of a battery of genes involved in life and death of the cell, and which is referred to as "the guardian of the genome". Dr. Arakawa has identified, characterised and reported over 20 p53-regulated target genes.

Recently his group discovered an unusual mechanism for mitochondrial quality control, in which the p53 pathway controls mitochondrial quality by repairing or eliminating unhealthy mitochondria, suggesting that cancer cells might accumulate unhealthy mitochondria due to p53 mutations. Maintenance of healthy mitochondria prevents aging, cancer, and a variety of degenerative diseases, therefore Dr Arakawa's research offers a new approach of cancer and mitochondrial quality control, suggesting that p53 is also a guardian of mitochondria.

Dr Mineo Kurokawa works in the department of Hematology and Oncology at the Graduate School of Medicine. For 20 years, he has studied the mechanisms of malignant transformation of hematopoietic stem cells (multipotent stem cells that give rise to all blood lineages) in order to elucidate the pathogenesis of blood malignancies. He focused on the role of transcription factors associated with human leukaemia. For instance he revealed the transforming activity of EVI1, a protein frequently activated in human leukaemia and elucidated its' functions that are involved in the prevention of cell death.

Through his pursuit of the pathogenetic significance of deregulated transcription factors in leukaemia, Dr Kurokawa has consistently contributed to the understanding of a mechanistic basis of leukaemia development and the identification of novel therapeutic targets of human haematological malignancies.

"We are proud to reward these very talented and inspiring scientists for their hard work and accomplishments. The jury's decision to nominate them was unanimous," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "We wish them a lot of luck for the future hoping their work will lead to major medical developments eventually benefiting the patients in the years to come."

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit:

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69

Additional Media Contacts
In London
Brian Hudspith
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Circassia Acquires North American and Japanese Rights to Dopexamine
2. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. GenVault Opens Japanese Subsidiary to Better Address Global Biobanking Market Growth
6. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
7. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
8. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
9. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
10. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
11. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier ... that it has been selected by The Michael J. ... cell lines to academic, pharmaceutical, and biotechnology organizations committed ... the United States , and more ... the United States , and more ...
(Date:10/8/2015)... Texas , Oct. 8, 2015 The 2015 ... of The University of Texas at Dallas. Aziz Sancar ... UT Dallas in 1977, is one of ... how cells continuously monitor and repair damaged DNA on a molecular ... in molecular and cell biology from UT Dallas ...
(Date:10/8/2015)... ST. LOUIS , Oct. 8, 2015 /PRNewswire/ ... that the Cerilliant ® brand within its ... its new bile acid reference standards product line ... the most routinely tested bile acids and their ... materials (CRMs) consist of lithocholic acid, taurocholic acid ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston Scientific ... start of the Boston Scientific Connected Patient Challenge ... in the use of remote patient monitoring to enhance ... and entrepreneurs can submit their ideas and collaborate on ... ). Cambridge, MA ...
Breaking Biology Technology:
... 2011 At the White House today, President Barack ... U.S. recipients of the 2010 Kavli Prizes to recognize ... for which the Prizes are awarded -- astrophysics, nanoscience ... Joined by the President,s science advisor, John ...
... Kingdom, June 6, 2011 Oxford BioMedicaplc ... gene therapy company, today announces that it has signed ... biotechnology company specialising in the development of engineered antibody ... engineer an in vivo diagnostic imaging agent ...
... Biosciences, a leading innovator in protein diagnostics, announces ... allows researchers to cost effectively accelerate their research ... Avantra,s proven QPDx™ BioChip platform. The QPDx™ platform ... using catalog or custom reagents. Avantra,s ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 Report Details ... far not quite delivered upon previous expectations of revenues, ... be the breakthrough year in which wearables begin to ... expected. One of the main reasons is the entrance ... not only the SmartWatches market, but the overall size ...
(Date:9/8/2015)... 8, 2015   TREW Marketing and ... Smart Marketing for Engineers TM : Content and ... reveals insightful findings about engineers, preferences for online content ... engineers most value and trust, and where they look ... technical audiences grapple with how to best implement online ...
(Date:9/2/2015)... September 2, 2015 ... implied in a system which uses identical human ... iris, vein, DNA and finger print. Increasing number ... develop such system which provides high level of ... Patterns and tokens are vulnerable to attacks. Furthermore, ...
Breaking Biology News(10 mins):
... blueprint of the rock pigeon, unlocking secrets about pigeons, Middle ... how mutations give pigeons traits like feather head crests. ... we know surprisingly little about their genetics," says Michael Shapiro, ... at the University of Utah. In the new study, ...
... and NEWTOWN, Pa., Jan. 31, 2013   Shareholder ... the acquisition of BioClinica, Inc. (NASDAQ: BIOC ... solutions to pharmaceutical, biotechnology, and medical device companies. ... On January 30, 2013, BioClinica announced that it had ...
... On January 30, 2013 ACS Nano published ... in the division of biomedical engineering at Brigham and ... that utilize nanotechnology to enhance the conductivity of materials ... cardiac patches put medicine a step closer to durable, ...
Cached Biology News:
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... 5 ml CELLection Dynabeads (4.5 m) coated ... epithelial antigen EpCAM and DNase Releasing Buffer. ... of epithelial tumour cells directly from blood, ... can be enriched from bone marrow. Enriched ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: